Novartis off to “strong” start, prompting guidance raise for 2025
Title
Novartis Delivers Strong Q1 2025 Results, Raises Full-Year Guidance
Keywords
- Novartis
- Q1 2025
- financial results
- revenue growth
- operating income
- earnings per share
- free cash flow
- guidance raise
- pharmaceutical industry
Key Facts
- Novartis reported a strong start to 2025, with first-quarter revenue rising 12% year-over-year to $13.2 billion, surpassing analyst expectations of $13.1 billion.
- Operating income increased by 38% year-over-year, reaching $4.66 billion in Q1 2025, compared to $3.37 billion in Q1 20243.
- Net income for the quarter was $3.61 billion, up from $2.69 billion in the same period last year3.
- Earnings per share (EPS) rose to $1.83, compared to $1.31 in Q1 20243.
- Novartis recorded a 66% surge in free cash flow, reaching $3.4 billion4.
- The strong performance was attributed to momentum from priority brands and robust global sales growth5.
- As a result of the better-than-expected start, Novartis raised its full-year 2025 guidance4.
- The company continues to focus on innovation and expanding approvals for key therapies across multiple markets5.
Sources:
3. https://www.novartis.com/sites/novartis_com/files/2025-04-interim-financial-report-en.pdf
4. https://www.tipranks.com/news/company-announcements/novartis-reports-strong-q1-2025-financial-performance
5. https://www.novartis.com/sites/novartis_com/files/q1-2025-investor-presentation.pdf